Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Declines By 59.4%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totaling 1,568 shares, a decrease of 59.4% from the May 31st total of 3,862 shares. Based on an average daily volume of 106,636 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Xtant Medical Price Performance

NYSEAMERICAN:XTNT traded up $0.01 on Monday, reaching $0.43. The stock had a trading volume of 46,877 shares, compared to its average volume of 148,732. The company has a quick ratio of 1.64, a current ratio of 3.34 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $59.74 million, a P/E ratio of 42.63 and a beta of -0.16. Xtant Medical has a 1-year low of $0.40 and a 1-year high of $0.95. The stock has a fifty day moving average price of $0.48 and a 200-day moving average price of $0.57.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its quarterly earnings data on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $20.88 million during the quarter, compared to analyst estimates of $20.16 million. Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on XTNT. BTIG Research reissued a “buy” rating and issued a $1.00 target price on shares of Xtant Medical in a report on Wednesday, May 13th. Craig Hallum reaffirmed a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $1.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in shares of Xtant Medical during the second quarter worth $26,000. Nantahala Capital Management LLC increased its position in Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after purchasing an additional 57,000,000 shares during the period. Mink Brook Asset Management LLC raised its holdings in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. Vanguard Group Inc. raised its holdings in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after purchasing an additional 104,159 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Xtant Medical during the 4th quarter valued at about $220,000. 69.33% of the stock is currently owned by institutional investors.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.